UK's cost-ef­fec­tive­ness gate­keep­er wants to pro­vide faster ac­cess to more new drugs

The UK’s ar­biter of cost-ef­fec­tive­ness de­ci­sions for new drugs, known as the Na­tion­al In­sti­tute for Health and Care Ex­cel­lence or NICE, is plot­ting a ma­jor …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER